Clinical Trial Update: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating CLN-978, a subcutaneously administered CD19-directed T cell engager, in subjects with Sjögren's syndrome. The study is sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• CLN-978

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Sjögren, Sjogren Disease | Phase 1 | Status: RECRUITING